Description
Product details
GLIEMPAFLOZIN LINA 25mg/5mg is a combination medication designed for individuals managing type 2 diabetes mellitus. It contains Empagliflozin (25mg) and Linagliptin (5mg), two potent anti-diabetic agents that work together to control blood sugar levels effectively. This medication is typically prescribed to patients who require dual therapy to achieve optimal glycemic control when diet and exercise alone are insufficient. Key Benefits : Effective Blood Sugar Control: Regulates blood glucose levels efficiently in patients with type 2 diabetes. Weight Management: Empagliflozin promotes weight loss by removing excess glucose from the body. Heart and Kidney Benefits: Shown to provide cardiovascular and renal protection, reducing the risk of heart failure. Lower Risk of Hypoglycemia: Minimal chances of low blood sugar episodes compared to other anti-diabetic medications. Convenient Dual Therapy: Combines two complementary mechanisms for enhanced glycemic control in a single tablet. How Does It Work? Empagliflozin (SGLT2 Inhibitor): This component blocks Sodium-Glucose Cotransporter-2 (SGLT2) in the kidneys, preventing glucose reabsorption and facilitating its elimination through urine. This leads to a significant reduction in blood sugar levels. Linagliptin (DPP-4 Inhibitor): It inhibits Dipeptidyl Peptidase-4 (DPP-4) enzyme, which increases incretin hormone levels. This enhances insulin secretion and suppresses glucagon production, leading to better post-meal glucose control. Directions for Use Take one tablet daily, preferably at the same time each day. Swallow the tablet whole with water, with or without food. Follow the dosage regimen prescribed by your healthcare provider. Regular monitoring of blood sugar levels is recommended. Side Effects Although GLIEMPAFLOZIN LINA 25mg/5mg is generally well-tolerated, some patients may experience: Frequent Urination: Due to glucose excretion through urine. Dehydration or Thirst: Increased urination may lead to mild dehydration. Urinary Tract Infections (UTIs): A common side effect associated with SGLT2 inhibitors. Nasal Congestion or Sore Throat: Occasionally observed with DPP-4 inhibitors. Gastrointestinal Discomfort: Mild nausea or diarrhea in some cases. Hypotension (Low Blood Pressure): Especially in patients with pre-existing conditions.
